Owing to the lack of ER, PR, and HER2 receptors, which are nowadays the available BC target therapies, TNBC presents poor prognosis, being the systemic chemotherapy (often using Dox) the mainstream treatment [142,143,144]. The gene discussed is PGR; the disease is breast cancer.